168 related articles for article (PubMed ID: 36807319)
1. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
Jukic T; Drobne D; Pusavec S; Ihan A; Stubljar D; Starc A
Med Sci Monit; 2023 Feb; 29():e939084. PubMed ID: 36807319
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
Jentzer A; Berger AE; Labetoulle R; Haccourt A; Roblin X; Paul S
Ther Drug Monit; 2018 Dec; 40(6):749-753. PubMed ID: 30439790
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
6. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.
Rocha C; Lago P; Fernandes S; Correia L; Portela F; Vieira AI; Patita M; Arroja B; Ministro P; Alves C; Dias CC; Magro F
Therap Adv Gastroenterol; 2020; 13():1756284820965790. PubMed ID: 33281935
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
11. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
13. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
15. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
Valdés-Delgado T; Aguado-Paredes A; Merino-Bohórquez V; Martín-Manzanares J; Alonso MM; Maldonado B; Castro L; Belvis M; Benítez B; Caunedo Á; Calleja MÁ; Argüelles-Arias F
Dig Dis Sci; 2024 Jan; 69(1):228-234. PubMed ID: 37943382
[TBL] [Abstract][Full Text] [Related]
16. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
17. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
20. Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.
Lim MH; Aluzaite K; Schultz M; Casey P
J Gastroenterol Hepatol; 2020 Aug; 35(8):1302-1306. PubMed ID: 31881552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
